Avecho Biotechnology Limited (AVEFF)
USD 0.0
(157.14%)
USD 0.0
(157.14%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -43.79 Thousand AUD | -125.57% |
| 2022 | 870.02 Thousand AUD | 71.29% |
| 2021 | 507.93 Thousand AUD | 110.84% |
| 2020 | 240.91 Thousand AUD | -94.01% |
| 2019 | 4.02 Million AUD | 475.62% |
| 2018 | 698.99 Thousand AUD | -33.85% |
| 2017 | 1.05 Million AUD | -16.01% |
| 2016 | 1.25 Million AUD | -17.4% |
| 2015 | 1.52 Million AUD | 9.88% |
| 2014 | 1.38 Million AUD | 122.12% |
| 2013 | 624 Thousand AUD | 13.25% |
| 2012 | 551 Thousand AUD | -62.67% |
| 2011 | 1.47 Million AUD | -68.02% |
| 2010 | 4.61 Million AUD | 518.77% |
| 2009 | 746 Thousand AUD | -68.83% |
| 2008 | 2.39 Million AUD | 56.71% |
| 2007 | 1.52 Million AUD | 29.63% |
| 2006 | 1.17 Million AUD | 561.8% |
| 2005 | 178 Thousand AUD | 0.0% |
| 2004 | - AUD | -100.0% |
| 2003 | 240.2 Thousand AUD | 72.79% |
| 2002 | 139.01 Thousand AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| 1997 | - AUD | 0.0% |
| 1996 | - AUD | 0.0% |
| 1995 | - AUD | 0.0% |
| 1994 | - AUD | 0.0% |
| 1993 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 103.59 Thousand AUD | 0.0% |
| 2024 Q1 | 103.59 Thousand AUD | 123.75% |
| 2023 Q2 | 213.79 Thousand AUD | 34.41% |
| 2023 Q3 | -180.96 Thousand AUD | -184.64% |
| 2023 Q4 | -436.28 Thousand AUD | -141.09% |
| 2023 Q1 | 159.06 Thousand AUD | 20.58% |
| 2023 FY | -222.49 Thousand AUD | -125.57% |
| 2022 FY | 870.02 Thousand AUD | 71.29% |
| 2022 Q3 | 117.98 Thousand AUD | -72.61% |
| 2022 Q1 | 278.57 Thousand AUD | 1623.4% |
| 2022 Q2 | 430.84 Thousand AUD | 54.66% |
| 2022 Q4 | 131.92 Thousand AUD | 11.81% |
| 2021 Q2 | -807.94 Thousand AUD | -1053.06% |
| 2021 Q1 | 84.77 Thousand AUD | 108.12% |
| 2021 Q4 | 16.16 Thousand AUD | -90.45% |
| 2021 FY | 507.93 Thousand AUD | 110.84% |
| 2021 Q3 | 169.19 Thousand AUD | 120.94% |
| 2020 Q4 | -1.04 Million AUD | -2456.03% |
| 2020 FY | 240.91 Thousand AUD | -94.01% |
| 2020 Q2 | -675.11 Thousand AUD | -986.46% |
| 2020 Q1 | 76.15 Thousand AUD | 110.47% |
| 2020 Q3 | 44.29 Thousand AUD | 106.56% |
| 2019 Q3 | 14.09 Thousand AUD | -99.55% |
| 2019 Q4 | -727.09 Thousand AUD | -5259.28% |
| 2019 Q2 | 3.11 Million AUD | 55.83% |
| 2019 FY | 4.02 Million AUD | 475.62% |
| 2019 Q1 | 1.99 Million AUD | 923.46% |
| 2018 Q2 | 225.29 Thousand AUD | 0.0% |
| 2018 Q4 | 195.18 Thousand AUD | 0.0% |
| 2018 Q3 | 195.18 Thousand AUD | -13.36% |
| 2018 FY | 698.99 Thousand AUD | -33.85% |
| 2018 Q1 | 225.28 Thousand AUD | 0.0% |
| 2017 Q2 | 381.88 Thousand AUD | -0.0% |
| 2017 Q1 | 381.88 Thousand AUD | 236.55% |
| 2017 FY | 1.05 Million AUD | -16.01% |
| 2016 Q1 | 516.09 Thousand AUD | 22.3% |
| 2016 Q3 | 113.47 Thousand AUD | -78.01% |
| 2016 Q2 | 516.09 Thousand AUD | -0.0% |
| 2016 Q4 | 113.47 Thousand AUD | 0.0% |
| 2016 FY | 1.25 Million AUD | -17.4% |
| 2015 Q4 | 421.97 Thousand AUD | 0.0% |
| 2015 FY | 1.52 Million AUD | 9.88% |
| 2015 Q1 | 331.5 Thousand AUD | -47.58% |
| 2015 Q2 | 331.5 Thousand AUD | 0.0% |
| 2015 Q3 | 421.97 Thousand AUD | 27.29% |
| 2014 Q1 | 154.5 Thousand AUD | 136.42% |
| 2014 FY | 1.38 Million AUD | 122.12% |
| 2014 Q4 | 632.37 Thousand AUD | 0.0% |
| 2014 Q3 | 632.37 Thousand AUD | 309.3% |
| 2014 Q2 | 154.5 Thousand AUD | 0.0% |
| 2013 Q3 | 226.2 Thousand AUD | 1359.41% |
| 2013 FY | 624 Thousand AUD | 13.25% |
| 2013 Q4 | -424.21 Thousand AUD | -287.53% |
| 2013 Q2 | 15.5 Thousand AUD | 0.0% |
| 2013 Q1 | 15.5 Thousand AUD | 0.0% |
| 2012 FY | 551 Thousand AUD | -62.67% |
| 2011 FY | 1.47 Million AUD | -68.02% |
| 2010 FY | 4.61 Million AUD | 518.77% |
| 2009 FY | 746 Thousand AUD | -68.83% |
| 2008 FY | 2.39 Million AUD | 56.71% |
| 2007 FY | 1.52 Million AUD | 29.63% |
| 2006 FY | 1.17 Million AUD | 561.8% |
| 2005 FY | 178 Thousand AUD | 0.0% |
| 2004 FY | - AUD | -100.0% |
| 2003 FY | 240.2 Thousand AUD | 72.79% |
| 2002 FY | 139.01 Thousand AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| 1997 FY | - AUD | 0.0% |
| 1996 FY | - AUD | 0.0% |
| 1995 FY | - AUD | 0.0% |
| 1994 FY | - AUD | 0.0% |
| 1993 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.374% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1695.613% |
| CSL Limited | 7.56 Billion USD | 100.001% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.037% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 124.805% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.284% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.456% |
| Qrons Inc. | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 86.293% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.83% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 162.564% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 64.753% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 9.25% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 131.171% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.011% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.292% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1511.831% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.447% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 166.631% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -28.243% |
| Mesoblast Limited | -35.16 Million USD | 99.875% |
| Marizyme, Inc. | 457.7 Thousand USD | 109.568% |
| Genus plc | 178.7 Million USD | 100.025% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.02% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 170.381% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 110.677% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -298.136% |
| ContraFect Corporation | -154 Thousand USD | 71.562% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 12.41% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 157.054% |
| IMV Inc. | -962.29 Thousand USD | 95.449% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 88.698% |
| MultiCell Technologies, Inc. | 49.32 USD | 88897.648% |
| ONE Bio Corp. | 20.12 Million USD | 100.218% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.109% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 189.56% |
| Q BioMed Inc. | -8988.00 USD | -387.261% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.155% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -183.941% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.099% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 96.164% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -784.39% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 55.089% |
| GB Sciences, Inc. | -624.00 USD | -6918.429% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 49.092% |
| HST Global, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -20955.288% |
| Enzolytics Inc. | 30.7 Thousand USD | 242.618% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 109.078% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.004% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 91.488% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 107.094% |
| Zenith Capital Corp. | - USD | Infinity% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -394.523% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 47.769% |
| Kadimastem Ltd | -630.13 Thousand USD | 93.05% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 104.433% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -270.046% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 124.805% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 103.227% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -51.017% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 109.731% |
| SYBLEU INC | 11.69 Thousand USD | 474.444% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.95% |
| Bioxytran, Inc. | -8285.00 USD | -428.606% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 88.259% |
| Neutra Corp. | 14.33 Thousand USD | 405.511% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 46.591% |
| PureTech Health plc | -1.6 Million USD | 97.268% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 95.626% |
| IXICO plc | 3.27 Million USD | 101.339% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 93.689% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 97.555% |
| CSL Limited | 7.7 Billion USD | 100.001% |
| Cellectis S.A. | 18 Thousand USD | 343.306% |